Alexander Tiffany, Maxim Elena, Cardwell Leah A, Chawla Aneesh, Feldman Steven R
a Department of Dermatology, Wake Forest School of Medicine , Center for Dermatology Research , Winston-Salem , NC , USA.
b Department of Pathology , Wake Forest School of Medicine , Winston-Salem , NC , USA.
J Dermatolog Treat. 2018 May;29(3):238-240. doi: 10.1080/09546634.2017.1365112. Epub 2017 Oct 2.
Atopic dermatitis (AD) is a common, chronic inflammatory skin disease characterized by pruritic, often lichenified, patches and plaques.
Data were obtained from the Humana database, a large claim-based database encompassing more than 20 million patients under a commercial healthcare insurance plan. Our cohort included 39,526 subjects who saw a dermatologist for a primary ICD-9 diagnosis of atopic dermatitis (691.8) between the years of 2010 and 2015. Subjects were stratified according to gender, age and race. Prescribed medication lists were obtained and sorted based on potential indication for atopic dermatitis.
The most common medications prescribed for atopic dermatitis in descending order were topical corticosteroids (60.2% of patients), oral antibiotics (17.3% of patients), antifungals (6.7% of patients), antihistamines (6.4% of patients), oral corticosteroids (5.9% of patients), calcineurin inhibitors (2.3% of patients) and emollients (1.2% of patients). Males ages 20-39 and 40-59 had the highest rates of oral steroids prescribed, at 9.2% and 9.8% of patients, respectively.
Presumably, individuals who are prescribed multiple courses of oral corticosteroids over time have severe atopic dermatitis with recalcitrance to other options. Given the side effect profile of oral corticosteroids, steroid-sparing systemic agents may be a better long-term option in the absence of contraindications.
特应性皮炎(AD)是一种常见的慢性炎症性皮肤病,其特征为瘙痒性、常呈苔藓化的斑块和斑片。
数据来自Humana数据库,这是一个基于理赔的大型数据库,涵盖超过2000万参加商业医疗保险计划的患者。我们的队列包括39526名在2010年至2015年间因原发性ICD-9诊断为特应性皮炎(691.8)而就诊皮肤科医生的受试者。受试者按性别、年龄和种族进行分层。获取所开药物清单,并根据特应性皮炎的潜在适应症进行分类。
按降序排列,特应性皮炎最常开具的药物为外用皮质类固醇(60.2%的患者)、口服抗生素(17.3%的患者)、抗真菌药(6.7%的患者)、抗组胺药(6.4%的患者)、口服皮质类固醇(5.9%的患者)、钙调神经磷酸酶抑制剂(2.3%的患者)和润肤剂(1.2%的患者)。20 - 39岁和40 - 59岁男性口服类固醇的处方率最高,分别为患者的9.2%和9.8%。
据推测,随着时间推移接受多个疗程口服皮质类固醇治疗的个体患有严重的特应性皮炎,对其他治疗方法具有顽固性。鉴于口服皮质类固醇的副作用,在没有禁忌证的情况下,减少类固醇用量的全身性药物可能是更好的长期选择。